{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:45:22Z","timestamp":1761093922584,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.anai.2017.04.022","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T15:12:17Z","timestamp":1494342737000},"page":"85-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia"],"prefix":"10.1016","volume":"119","author":[{"given":"Kris","family":"McGrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Kalhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-9086","authenticated-orcid":false,"given":"Lauren","family":"Leighton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2017.04.022_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.iac.2015.04.001","article-title":"Evaluation and differential diagnosis of persistent marked eosinophilia","volume":"35","author":"Casey","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2017.04.022_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12016-015-8491-x","article-title":"Eosinophilic drug allergy","volume":"50","author":"Kuruvilla","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2017.04.022_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.iac.2015.05.006","article-title":"Management of hypereosinophilic syndromes","volume":"35","author":"Roufosse","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2017.04.022_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","article-title":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR\u03b1","volume":"36","author":"Baumgartner","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.anai.2017.04.022_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.leukres.2010.08.022","article-title":"Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib","volume":"35","author":"Valent","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.anai.2017.04.022_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1600-0609.2011.01603.x","article-title":"Cross-Intolerance to imatinib, dasatinib, nilotinib therapy in a patient with chronic myeloid leukemia","volume":"86","author":"Novitizky-Basso","year":"2011","journal-title":"Eur J Hematol"},{"key":"10.1016\/j.anai.2017.04.022_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120617303381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120617303381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:17:42Z","timestamp":1761052662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120617303381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1081120617303381"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2017.04.022","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2017.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}